SIREN : 812266773
FINANCIERE DE LA CURE is a French company founded 10 years ago, specialized in the sector Activités des sociétés holding. Based in PARIS (75008), this company of category PME shows in 2024 a revenue of 150 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 150 000 € | 134 583 € | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | 141 580 € | 616 571 € | 379 197 € | 523 808 € | 287 450 € | 192 035 € | 138 092 € | 186 928 € |
| EBITDA | 138 720 € | -197 668 € | -1 759 € | -3 137 € | -2 367 € | -3 161 € | -2 589 € | -5 037 € |
| Net margin | 94.4% | 458.1% | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, FINANCIERE DE LA CURE achieves revenue of 150 k€. Over the period 2023-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +11.5%. Vs 2023, growth of +11% (135 k€ -> 150 k€). After deducting consumption (0 €), gross margin stands at 150 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 139 k€, representing 92.5% of revenue. Positive scissor effect: EBITDA margin improves by +239.4 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 142 k€, i.e. 94.4% of revenue. This profit can be retained or distributed to shareholders.
150 000 €
150 000 €
138 720 €
138 720 €
141 580 €
92.5%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 99%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 93.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.052%
99.343%
93.885%
0.01
In 2024, the debt ratio of FINANCIERE DE LA CURE (0.05) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of FINANCIERE DE LA CURE (99.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of FINANCIERE DE LA CURE (0.01) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 16514.49. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.5x. Danger: operating income does not cover interest charges, unsustainable situation.
16514.487
0.476
In 2024, the liquidity ratio of FINANCIERE DE LA CURE (16514.49) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of FINANCIERE DE LA CURE (0.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 239 days. Excellent situation: suppliers finance 239 days of the operating cycle (retail model). WCR is negative (-19 days): operations structurally generate cash.
-8 031 €
0 j
239 j
0 j
-19 j
Based on 54 transactions of similar company sales
in 2024,
the value of FINANCIERE DE LA CURE is estimated at
403 249 €
(range 99 626€ - 820 991€).
With an EBITDA of 138 720€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare FINANCIERE DE LA CURE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of FINANCIERE DE LA CURE in 2024 is 150 k€.
Yes, FINANCIERE DE LA CURE generated a net profit of 142 k€ in 2024.
The headquarters of FINANCIERE DE LA CURE is located in PARIS (75008), in the department Paris.
The tax return of FINANCIERE DE LA CURE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
FINANCIERE DE LA CURE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.